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Abstract
Clinical	research	in	the	treatment	of	patients	with	congenital	heart	disease	(CHD)	is	
limited	by	the	wide	variety	of	CHD	manifestations	and	therapeutic	options	as	well	as	
the	generally	 low	incidence	of	CHD.	The	availability	of	comprehensive,	contempo-
rary	outcomes	studies	 is	therefore	 limited.	This	 inadequacy	may	result	 in	a	 lack	of	
data‐driven	 medical	 decision	 making.	 In	 2013,	 clinician	 scientists	 at	 two	 centers	
began	a	research	collaboration,	the	Congenital	Catheterization	Research	Collaborative	
(CCRC).	Over	time,	the	CCRC	has	grown	to	include	nine	cardiac	centers	from	across	
the	United	States,	with	a	common	data	coordinating	center.	The	CCRC	seeks	to	gen-
erate	 high‐quality,	 contemporary,	 statistically	 robust,	 and	 generalizable	 outcomes	
research	which	 can	 help	 address	 important	 clinical	 questions	 in	 the	 treatment	 of	
CHD.	To	date,	 the	CCRC	has	 reported	on	multicenter	outcomes	 in:	neonates	with	
congenital	 aortic	 stenosis,	 infants	 undergoing	 right	 ventricular	 decompression	 for	
pulmonary	atresia	and	intact	ventricular	septum,	and	infants	with	ductal‐dependent	
pulmonary	blood	flow.	The	CCRC	has	been	successful	at	leveraging	large	multicenter	
cohorts	of	patients	in	a	contemporary	period	to	perform	comparative	studies.	In	the	
future,	the	CCRC	plans	to	continue	to	perform	hypothesis‐driven	retrospective	and	
prospective	observational	studies	of	CHD	populations	where	controversy	exists	or	
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1  | INTRODUC TION
A	high	degree	of	variability	attends	nearly	all	 forms	of	therapy	for	
patients	with	congenital	heart	disease	 (CHD).	This	variability	 is	 in-
herent	in	medicine	and	reflects	a	number	of	immovable	features	of	
health	care	delivery.	Temporal	variability	is	likely	due	to	factors	such	
as	improved	understanding	of	pathophysiology	and	improved	thera-
peutics.	Technological	advances	have	not	only	continued	to	emerge,	
but	have	been	introduced	at	an	accelerating	rate	over	the	past	3	de-
cades.	In	areas	as	disparate	as	ventricular	assist	devices,	stent	tech-
nology,	 and	 anticoagulation	 therapies,	 innovations	 are	 introduced	
regularly.	Regional	and	center‐based	variability	reflects	geographic	
and	at	times	individual	practitioner	preferences,	but	may	also	reflect	
population	and	cultural	biases,	preconceptions,	and	vulnerabilities.
These	variations	make	it	difficult	to	interpret	outcomes	following	
both	established,	conventional	therapies	as	well	as	novel	interven-
tions.	The	difficulty	 is	particularly	notable	 in	 the	 field	of	pediatric	
cardiology,	where	small	populations	with	anatomically	heterogenous	
cardiac	 malformations	 seemingly	 preclude	 comprehensive	 review	
and	statistical	comparison.	For	example,	despite	the	fact	that	patent	
ductus	 arteriosus	 (PDA)	 stenting	has	been	performed	 in	neonates	
with	 cyanotic	 CHD	 since	 1991,	 the	 largest	 single‐center	 outcome	
studies	 evaluating	 the	 safety	 and	 efficacy	 of	 this	 procedure	 have	
been	limited	to	small	cohorts	of	8‐64	patients,	with	larger	cohorts	
spanning	broad	eras	(Figure	1).1-8	Over	the	inclusion	periods	in	those	
studies,	 concomitant	 advances	 in	 catheter	 and	 stent	 technology	
make	 it	 difficult	 to	 generalize	 the	 published	 outcomes	 reflecting	
older	 technologies	 to	contemporary	practice.	Further,	with	no	ap-
propriate	control	arms	in	such	studies,	determination	of	superiority	
of	therapy	is	not	possible.
Given	 the	 relatively	 low	 incidence	of	particular	 forms	of	CHD,	
and	institutional	and	regional	practice	patterns,	we	sought	to	use	a	
multicenter	approach	to	CHD	research	to	mitigate	these	hindrances.	
We	 created	 a	multicenter	 research	 collaborative,	 now	 termed	 the	
Congenital	Catheterization	Research	Collaborative	(CCRC),	in	2013.	
Originally	 consisting	 of	 two	 centers,	 the	 CCRC	 is	 now	 comprised	
of	nine	pediatric	cardiac	centers	from	across	the	United	States.	By	
design,	 the	 CCRC	 includes	 both	 medium‐	 and	 high‐volume	 geo-
graphically	diverse	cardiac	centers.	Despite	differences	in	treatment	
strategies	 in	 some	 areas	 of	 CHD,	 all	 centers	 offer	 comprehensive	
cardiac	care,	and	importantly	have	complementary	clinical	and	aca-
demic	missions.	The	goal	of	the	CCRC	is	to	enhance	the	understand-
ing	of	the	pathophysiology	of	CHD	and	the	outcomes	following	CHD	
interventions.	Our	research	methods	rely	on	leveraging	multicenter,	
contemporary	 clinical	 data	 from	 our	 network	 of	 diverse	 cardiac	
centers.
The	mission	of	the	CCRC	is	to	improve	the	outcomes	for	patients	
with	CHD	by	undertaking	hypothesis‐driven	research	with	a	special	
where	novel	interventions	or	therapies	have	emerged.	Quality	improvement	efforts	
including	lesion‐specific	registry	development	may	be	an	additional	potential	future	
target.
K E Y W O R D S
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F I G U R E  1  Pediatric	cardiology	studies	compared	by	span	of	
years	and	size	of	Cohort	included.	These	scatter	plots	demonstrate	
the	range	of	studies	reporting	outcomes	on	pulmonary	atresia	
with	intact	ventricular	septum	(PA‐IVS)	in	Panel	A,	and	on	stenting	
of	the	patent	ductus	arteriosus	(PDA)	in	Panel	B.	Size	of	cohort	
is	indicated	on	the	vertical	axes,	and	span	of	study	(years)	is	
indicated	on	the	horizontal	axes.	Previous	publications	in	PA‐IVS	
spanned	many	years,	up	to	28	years,	in	order	to	achieve	cohorts	
of	40‐60	patients.	Conversely,	the	CCRC	PA‐IVS	study	included	
99	patients	in	a	span	of	10	years	(orange	circle)	(A).	Studies	
evaluating	outcomes	following	PDA	stenting	(B)	likewise	included	
small	cohorts	or	conversely	achieved	larger	cohorts	by	including	
procedures	performed	>10	years	earlier.	However,	the	CCRC	PDA	
stent	study	included	106	neonates	in	an	8‐year	span	(orange	circle)	
[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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focus	on	areas	of	innovation	within	pediatric	and	adult	congenital	in-
terventional	cardiology.	The	goal	of	the	current	paper	is	to	describe	
the	rationale	for	the	creation	of	the	CCRC,	the	projects	achieved	to	
date,	and	the	future	directions	of	our	collaboration.
2  | HISTORY
The	CCRC	began	 in	2013	when	clinician	scientists	from	Cincinnati	
Children's	 Hospital	 Medical	 Center	 and	 Children's	 Healthcare	 of	
Atlanta	collaborated	to	study	 the	 relationship	between	valve	mor-
phology	and	outcomes	following	balloon	aortic	valvuloplasty.9	The	
collaboration	proved	successful	not	only	academically,	but	because	
the	 collaborating	 investigators	 found	 they	 could	 reliably	work	 to-
gether,	 across	 geographic	 and	 technological	 barriers.	 Web‐based	
video	 conference	 calls	 were	 held	 where	 echocardiograms	 and	
catheterization	 angiograms	were	 jointly	 reviewed	and	 interpreted.	
These	video	conferences	facilitated,	for	example,	consistent	meas-
urements	 of	 unique,	 nuanced	 echocardiographic	 parameters.	 This	
allowed	for	a	high	degree	of	interobserver	reliability	even	in	the	set-
ting	of	challenging	anatomic	 substrates.	The	multicenter	approach	
led	to	enhanced	appreciation	for	differing	approaches	to	aspects	of	
patient	 care	with	 congenital	 aortic	 stenosis,	 including	methods	 of	
valve	 annulus	measurement	 and	 technical	 performance	of	balloon	
aortic	valvuloplasty.
In	 2015,	 the	 CCRC	 grew	 to	 include	 investigators	 from	 the	
Children's	 Hospital	 of	 Philadelphia	 and	 Texas	 Children's	 Hospital.	
The	 resultant	 larger	CCRC	group,	which	would	 go	on	 to	 form	 the	
executive	committee,	sought	to	understand	factors	associated	with	
poor	outcomes	 in	children	with	pulmonary	atresia	and	 intact	ven-
tricular	 septum	 (PA‐IVS).	 Previous	 reports	 on	 PA‐IVS	 had	 largely	
been	limited	to	single‐center,	small	cohort	studies,	and	many	of	the	
larger	series	were	hindered	by	a	broad	span	of	inclusion	dates	(some	
spanning	multiple	decades	of	institutional	experience),	or	very	small	
cohorts	where	more	contemporary	approaches	were	employed	but	
statistical	 power	was	wanting	 (Figure	 1).10-16	 The	CCRC	 studied	 a	
contemporary,	relatively	large	cohort	of	neonates	with	PA‐IVS.	We	
evaluated	 a	 host	 of	 echocardiographic	 and	 hemodynamic	 factors	
and	 identified	 that	 preintervention	 tricuspid	 regurgitation	was	 as-
sociated	with	a	host	of	important	clinical	end	points	following	right	
ventricle	decompression	in	neonates	with	PA‐IVS.17	Additional	anal-
yses	 led	 to	 an	 enhanced	 understanding	 of	 the	 importance	 of	 nu-
anced	technical	variables	on	outcomes.	As	an	example,	we	reported	
that	higher	radiofrequency	energy	application	was	associated	with	
complications	such	as	cardiac	perforation.18
The	 study	 which	 the	 CCRC	 pursued	 next	 was	 a	 comparison	
of	 outcomes	 following	 transcatheter	 PDA	 stenting	 versus	 surgi-
cal	 systemic‐to‐pulmonary	artery	shunts	 (ie,	BT	shunts)	 in	 infants	
with	ductal‐dependent	pulmonary	blood	 flow.	Prior	 to	 this	 study,	
published	reports	were	limited	to	small	case	series	of	PDA	stenting	
procedures	or	rarely,	even	smaller	cohorts	where	outcomes	follow-
ing	PDA	stenting	were	 compared	 to	 those	 following	BT	 shunt.	 In	
both	 types	 of	 studies,	 generalization	 of	 results	was	 restricted	 by	
small	 cohort	 size,	 poor	 statistical	 power,	 and	 institutional	 prefer-
ences.	Particularly	 in	 the	case	of	 the	comparative	studies,	 results	
were	confounded	by	indication,	as	neonates	undergoing	PDA	stent-
ing	had	undeniably	different	risk	factors	when	compared	to	the	BT	
shunt	cohorts.3,8	The	CCRC	leveraged	a	relatively	large	multicenter	
population,	all	palliated	within	the	past	10	years,	which	reflects	the	
current	era	of	surgical	and	transcatheter	techniques	and	available	
devices.	Importantly,	this	cohort	size	allowed	for	propensity	score	
adjustment	to	account	for	confounding	by	indication,	including	in-
herent	 differences	 in	 cardiac	 anatomy,	 expected	 physiology,	 and	
other	 patient‐	 and	 center‐specific	 factors.19	 Ensuing	 studies	 from	
this	 cohort	 were	 performed	 which	 again	 highlighted	 important	
technical	 factors	 to	 consider	when	performing	PDA	 stenting,	 the	
impact	of	the	underlying	PDA	morphology	on	the	outcomes	follow-
ing	PDA	stenting,	and	the	impact	of	palliative	strategy	on	the	cost	
of	care.
Investigators	from	five	additional	institutions	(Table	1)	have	since	
joined	 the	 CCRC	 including	 members	 from	 Vanderbilt	 University,	
University	 of	 Alabama—Birmingham,	 University	 of	 California	 San	
Francisco,	University	of	Michigan,	and	Washington	University	in	St.	
Louis.	New	and	ongoing	studies,	outlined	below,	will	include	patients	
treated	at	all	9	centers.	With	the	inclusion	of	new	members	to	the	
CCRC,	the	executive	committee	recognized	a	need	to	both	formal-
ize	the	processes	for	conducting	research	and	also	to	introduce	the	
CCRC	methodology	to	new	investigators.	For	this	reason,	we	devel-
oped	an	onboarding	structure	for	new	members	which	helps	each	
investigator	to	understand	the	roles,	expectations,	and	mechanisms	
the	site	principal	investigator	assumes	within	the	collaborative.
Whenever	 possible,	 the	 CCRC	 draws	 from	 expertise	 beyond	
the	membership	 of	 the	CCRC.	Cardiology	 subspecialists	 in	 nonin-
vasive	imaging,	in	particular,	are	important	collaborators	and	indeed	
leaders	 of	 research	 efforts.20	 In	 these	 studies,	 imaging	 specialists	
have	played	an	important	role	in	assigning	anatomic	risk	factors.9,17 
Surgical	colleagues	were	included	from	the	outset	in	our	first	com-
parative	study	between	BT	shunt	and	PDA	stent.19	The	CCRC	also	
places	 a	 high	priority	 on	mentoring	of	 junior	 faculty	 and	 trainees,	
with	 active	 roles	 in	 research	projects.	Close	 collegial	 relationships	
with	other	important	members	of	the	congenital	cardiac	community	
help	ensure	our	work	minimizes	potential	bias	and	reflects	the	best	
available	science.
3  | CCRC CULTURE
While	 developing	 our	 bylaws	 and	 guidelines,	 the	 CCRC	 executive	
committee	 conferred	 with	 representatives	 from	 established	 and	
respected	 collaborative	 organizations,	 in	 particular	 leaders	 from	
the	Pediatric	Heart	Network	(PHN),	the	Pediatric	Heart	Transplant	
Study	(PHTS),	the	Pediatric	Cardiac	Critical	Care	Collaborative	(PC4),	
and	the	Pediatric	Acute	Care	Cardiology	Collaborative	 (PAC3).21-24 
These	collaborations	each	have	unique	goals,	administrative	struc-
tures,	and	data	collection	instruments	and	yet	their	experiences	and	
guidance	were	invaluable	in	creating	the	administrative	and	academic	
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structure	of	our	collaboration.	Leaders	from	these	collaborations	are	
routinely	invited	to	CCRC’s	in‐person	meetings	to	provide	ongoing	
advice	to	the	executive	committee.	Similarly,	members	of	the	CCRC	
have	been	invited	to	serve	on	local	and	national	career	development	
panels—particularly	focusing	on	the	benefits	academically	and	pro-
fessionally	associated	with	multicenter	collaborative	research.
Several	 attributes	 separate	 the	 CCRC	 from	 other	 seemingly	
similar	groups.	One	important	distinction	is	that	the	CCRC	is	not	a	
quality	 improvement	 registry	 such	as	 the	 Improving	Pediatric	 and	
Adult	Congenital	Treatments	(IMPACT)	Registry,	Congenital	Cardiac	
Catheterization	Project	on	Outcomes	(C3PO),	or	PC4.23,25,26	Rather,	
the	CCRC	undertakes	hypothesis‐driven	retrospective	and	prospec-
tive	observational	 research,	 the	 focus	of	which	 is	 often,	 although	
not	 exclusively,	 related	 to	 outcomes	 following	 interventional	
procedures.
Given	the	inherent	limitations	of	retrospective	research,	it	is	im-
perative	that	the	CCRC	develops	and	adheres	to	rigorous	methods	
and	timely	data	collection	to	enhance	the	rigor,	quality,	and	value	of	
our	research.	These	critical	methods	include:
A—use	of	contemporary	clinical	data	reflecting	up‐to‐
date	interventional,	imaging,	and	surgical	approaches.
B—highly	 granular	 and	 accurate	 data	 collection	 re-
flecting	a	comprehensive	data	auditing	process.
C—pooling	 of	 contemporary	 data	 across	 multiple	
sites,	 providing	 increased	 statistical	 power	 despite	
relatively	short	inclusion	periods.
Each	study	proposal	undergoes	a	review	by	the	New	Study	Proposal	
Committee	chair	as	well	as	the	Executive	Committee.	Proposals	with	
well‐defined	clinical	end	points	and	compelling	clinical	questions	are	
prioritized.	The	CCRC	reviews	such	proposals	and	has	adopted	a	scor-
ing	format	based	upon	the	National	Institutes	of	Health	Study	Section	
process.27	After	the	review	of	proposals	is	undertaken,	necessary	data	
elements	are	provided	and	a	case	report	form	(CRF),	data	dictionary,	
and	 Manual	 of	 Operations	 (MOO)	 are	 created.	 Data	 programming	
within	Research	Electronic	Data	Capture	(REDCap)	allows	for	secure	
web‐based	electronic	data	entry	among	the	CCRC	sites.28	The	data-
bases	are	created	and	maintained	by	the	CCRC	data	coordinating	cen-
ter	(DCC),	The	Children's	Healthcare	of	Atlanta.
Another	critical	aspect	of	 the	CCRC	 is	our	culture	of	 transpar-
ency	and	democratic	structure.	Specifically,	the	expectation	among	
the	CCRC’s	participants	is	that	all	investigators	share	in	the	academic	
workload,	the	academic	credit	as	well	as	the	organizational	respon-
sibilities.	Authorship	responsibilities	and	assignments	rotate	so	that	
each	member	 of	 the	 CCRC	 remains	 fully	 engaged,	 enjoys	 profes-
sional	growth	and	satisfaction,	and	can	ultimately	help	mentor	 fu-
ture	CCRC	members.	This	concept,	we	believe,	will	enable	the	CCRC	
to	remain	a	high‐quality	clinically	relevant	research	collaboration	for	
TA B L E  1  Members	of	the	congenital	catheterization	research	collaborative
Individual University affiliate Hospital affiliate Membership
Christopher	J.	Petit,	MD Emory	University	School	of	Medicine,	
Atlanta,	Georgia
Children’s	Healthcare	of	Atlanta President
Member	since	2013
Bryan	H.	Goldstein,	MD University	of	Cincinnati,	Cincinnati,	Ohio Cincinnati	Children’s	Hospital	
Medical	Center
Vice‐President
Chair, Finance Committee
Member	since	2013
Courtney	M.	McCracken,	PhD Emory	University	School	of	Medicine,	
Atlanta,	Georgia
Children’s	Healthcare	of	Atlanta Chair—Biostatistics
Member	since	2013
Athar	M.	Qureshi,	MD Baylor	College	of	Medicine,	Houston,	Texas Texas	Children’s	Hospital Chair—New Studies 
Committee
Member	since	2015
Andrew	C.	Glatz,	MD	MSCE University	of	Pennsylvania,	Philadelphia,	
Pennsylvania
Children’s	Hospital	of	Philadelphia Chair—Scientific 
Committee
Member	since	2015
George	T.	Nicholson,	MD Vanderbilt	University,	Nashville,	Tennessee Monroe	Carell	Jr	Children’s	
Hospital
Member	since	2017
Jeffery	Meadows,	MD University	of	California—San	Francisco,	San	
Francisco,	California
UCSF	Benioff	Children’s	Hospital Member	since	2017
Jeffrey	D.	Zampi,	MD University	of	Michigan,	Ann	Arbor,	Michigan CS	Mott	Children’s	Hospital Member	since	2018
Shabana	Shahanavaz,	MBBS Washington	University,	St.	Louis,	Missouri St.	Louis	Children’s	Hospital Member	since	2018
Mark	A.	Law,	MD University	of	Alabama—Birmingham,	
Birmingham,	Alabama
Children’s	of	Alabama Member	since	2018
Joelle	A.	Pettus,	MPH	MSW Emory	University	School	of	Medicine,	
Atlanta,	Georgia
Children’s	Healthcare	of	Atlanta Program	Manager	since	
2018
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years	to	come,	as	more	 junior	members	begin	to	 lead	CCRC’s	aca-
demic	and	organizational	efforts.
4  | CCRC ORGANIZ ATIONAL STRUC TURE 
AND FINANCES
The	CCRC	has	 developed	 a	 number	 of	 committees,	 each	 of	which	
focuses	on	a	unique	aspect	of	our	mission	(Figure	2).	The	executive	
committee	comprised	of	4	founding	members	of	the	CCRC	plus	1‐2	
at‐large	members	who	are	elected	to	serve	2‐year	terms.	The	role	of	
the	executive	 committee	 is	 to	ensure	 the	goals	 and	mission	of	 the	
CCRC	are	sustained,	that	academic	roles	and	credit	are	appropriately	
and	equitably	distributed,	and	that	studies	continue	to	be	completed	
efficiently	but	also	with	appropriate	scientific	rigor.	Committees	func-
tion	to	enhance	the	ability	of	the	CCRC	to	undertake	both	large‐scale	
and	focused	projects.	The	Finance	Chair	oversees	the	fiscal	budget,	
oversees	payment	of	dues,	and	assists	with	philanthropic	efforts.	The	
Scientific	 Committee	Chair	 advises	 each	 PI	 during	 the	 formulation	
of	each	new	study	and	oversees	the	analytic	plan.	The	Biostatistics	
Chair	advises	investigators	on	methodological	approaches	which	en-
hance	the	capabilities	to	perform	rigorous	statistics,	to	minimize	se-
lection	bias,	and	to	control	for	other	obvious	and	subtle	confounders.	
The	New	Studies	Chair	 focuses	on	evaluating	new	study	proposals	
not	only	to	evaluate	scientific	merit,	but	also	to	prioritize	studies,	and	
to	anticipate	and	promote	affiliated,	ancillary	studies.
Finances	of	 the	CCRC	are	 sustained	 through	a	 combination	of	
annual	member	dues	as	well	as	philanthropy.	Each	principal	investi-
gator's	institution	has	committed	to	annual	dues	which	support,	to	
date,	the	majority	of	the	administrative	functions	of	the	CCRC.	The	
costs	 associated	with	 biannual	 in‐person	meetings	 are	 largely	 un-
derwritten	by	the	CCRC.	Currently,	the	CCRC	enjoys	important	phil-
anthropic	support	from	generous	donors	who	support	the	mission	
of	 the	CCRC	as	well	 as	 the	 individual	 clinicians	who	comprise	 the	
collaborative.	In	many	cases,	these	donors	are	parents	of	children	or	
relatives	with	congenital	heart	disease.	To	date,	philanthropic	sup-
port	has	facilitated	the	hiring	of	a	program	manager,	who	is	based	at	
the	DCC	and	oversees	the	regulatory	and	administrative	functions	
of	the	CCRC.	Grant	funding	sources	will	be	considered	as	the	col-
laborative	focus	on	larger	scale	prospective	observational	studies.
The	CCRC	holds	a	biannual	in‐person	meeting	in	Atlanta,	at	the	
DCC.	 These	 2‐3‐day	 in‐person	meetings	 are	 critical	 for	 both	 aca-
demic	 success	 and	organizational	momentum.	The	meetings	 allow	
for	in‐depth	academic	project	review,	including	evaluation	of	study	
analyses	with	investigators	and	statisticians	on	site,	with	presenta-
tions	and	updates	given	by	the	principal	investigator	of	each	unique	
study	and	writing	group.	Further,	the	meetings	allow	for	new	study	
proposals	 to	be	presented,	 refined,	and	planned.	The	CCRC	mem-
bers	 also	 use	 the	meetings	 to	 discuss	 the	 organizational	 strategic	
vision,	review	CCRC	finances,	and	plan	for	the	introduction	of	new	
members	when	appropriate.	The	in‐person	meetings,	combined	with	
monthly	conference	calls	and	webinars,	ensure	regular	communica-
tion	and	an	open	culture	where	ideas,	criticisms,	and	disagreements	
are	 shared,	and	a	durable	collegial	 relationship	among	members	 is	
both	established	and	maintained.	Importantly,	the	professional	and	
social	 network	which	has	developed	within	 the	 collaborative	over	
time	among	the	CCRC	investigators	has	facilitated	an	ongoing	dedi-
cation	to	career	development,	professional	support,	and	leadership	
development	for	all	CCRC	members.
5  | CCRC DATA QUALIT Y AND AUDITING
The	data	auditing	process	has	matured	over	the	initial	years	of	the	
CCRC’s	existence.	With	 larger	cohort	studies	 involving	an	 increas-
ingly	broad	span	of	data	points,	 it	became	necessary	 to	 introduce	
F I G U R E  2  Congenital	catheterization	research	collaborative	administrative	structure.	This	graph	details	the	leadership	and	the	
administrative	structure	of	the	Congenital	Catheterization	Research	Collaborative	(CCRC).	Roles	within	the	CCRC	are	distributed	and	may	
rotate	to	ensure	that	each	member	is	highly	engaged	in	the	administrative	and	academic	functions	of	our	collaborative	[Colour	figure	can	be	
viewed	at	wileyonlinelibrary.com]
346  |     PETIT ET al.
a	 thorough	auditing	process.	The	executive	 committee,	 again,	dis-
cussed	 the	 issue	of	 data	quality	with	 leaders	of	 other	multicenter	
collaboratives,	notably	 the	PC4	 registry.	Ultimately,	we	utilize	a	2‐
step	approach	to	ensure	data	quality:	data	entry	training	and	interval	
data	auditing.
Prior	to	the	opening	of	new	study	REDCap	databases,	the	CCRC	
Program	Manager	 and	Biostatistics	Chair	 develop	 a	 study‐specific	
training	module	 for	 all	CCRC	principal	 investigators,	 study	coordi-
nators,	and	affiliated	data	entry	personnel	from	each	site.	REDCap	
data	entry	is	reviewed,	with	Data	Dictionary	elements	and	the	MOO	
explained.	Each	site	enters	2‐3	sample	patients	and	then	these	are	
reviewed	with	the	CCRC	Program	Manager.	Once	the	entries	are	re-
viewed	and	the	data	entry	personnel	from	a	given	site	understand	
the	data	elements	and	nature	of	data	entry,	the	site	is	then	permitted	
to	proceed	with	complete	data	entry	for	that	study.
The	program	manager,	study	biostatisticians	as	well	as	the	study	
lead	 investigator	 with	 assistance	 from	 the	 Scientific	 Committee	
chair	will	conduct	audits	of	data	on	regular	intervals.	Random	cases	
(10%‐20%	of	total	cohort	per	site),	assigned	by	the	Biostatistics	Chair,	
will	 be	 reviewed	by:	 (1)	 notification	 of	 the	 site	 principal	 investiga-
tor	 so	 that	 primary	 documents	 (eg,	 operative	 reports,	 echocardio-
gram	reports,	catheterization	reports)	can	be	electronically	captured	
and	uploaded	into	REDCap	and	(2)	primary	document	review	at	the	
DCC.	Auditors	will	then	adjudicate	the	entered	data	with	the	primary	
source	 documents	 to	 ensure	 completeness	 and	 accuracy	 of	 data	
entry.	Discrepancies	will	then	be	resolved.	When	systematic,	recur-
ring	errors	are	noted,	retraining	of	the	involved	site	personnel	may	
be	necessary.	Errors	in	data	extraction	and	entry	are	recorded	and	
these	challenges	in	data	entry	discussed	during	monthly	conference	
calls	to	ensure	maximal	efficiency	and	mutual	benefit	across	all	sites.
TA B L E  2  List	of	congenital	catheterization	research	collaborative	publications	and	studies	to	date
Relation	of	aortic	valve	morphologic	characteristics	to	aortic	valve	insufficiency	and	residual	
stenosis	in	children	with	congenital	aortic	stenosis	undergoing	balloon	valvuloplasty30
American	Journal	of	Cardiology—2016
Aortic	valve	morphology	correlates	with	left	ventricular	systolic	function	and	outcome	in	children	
with	congenital	aortic	stenosis	prior	to	balloon	aortic	valvuloplasty9
Journal	of	Invasive	Cardiology—2016
Outcomes	after	decompression	of	the	right	ventricle	in	infants	with	pulmonary	atresia	with	intact	
ventricular	septum	are	associated	with	degree	of	tricuspid	regurgitation:	results	from	the	
Congenital	Catheterization	Research	Collaborative17
Circulation:	Cardiovascular	
Interventions—2017
A	comparison	between	patent	ductus	arteriosus	stent	and	modified	Blalock‐Taussig	shunt	as	
palliation	for	infants	with	ductal‐dependent	pulmonary	blood	flow:	insights	from	the	congenital	
catheterization	research	collaborative31
Circulation—2018
Technical	factors	are	associated	with	complications	and	repeat	intervention	in	neonates	undergoing	
transcatheter	right	ventricular	decompression	for	pulmonary	atresia	and	intact	ventricular	
septum:	results	from	the	Congenital	Catheterization	Research	Collaborative32
Cardiology	in	the	Young—2018
Echocardiographic	predictors	of	biventricular	physiology	in	pulmonary	atresia	and	intact	ventricular	
septum:	results	from	the	congenital	catheterization	research	collaborative20
Congenital	Heart	Disease—2018
Classification	scheme	for	ductal	morphology	in	cyanotic	patients	with	ductal‐dependent	pulmo-
nary	blood	flow	and	association	with	outcomes	of	patent	ductus	arteriosus	stenting33
Catheterization	and	Cardiovascular	
Interventions—In	Press
Blalock‐Taussig	shunt	versus	patent	ductus	arteriosus	stent	as	first	palliation	for	ductal	dependent	
pulmonary	circulation	lesions:	a	review	of	the	literature34
Congenital	Heart	Disease—2018
Stenting	of	the	ductus	arteriosus	for	ductal‐dependent	pulmonary	blood	flow—current	techniques	
and	procedural	considerations35
Congenital	Heart	Disease—2018
Use	of	carotid	and	axillary	artery	approach	in	patent	ductus	arteriosus	stenting:	a	multicenter	study	
from	the	congenital	catheterization	research	collaborative36
Under	review
Differences	in	cost	by	palliation	strategy	for	infants	with	ductal‐dependent	pulmonary	blood	flow:	
analysis	of	data	from	the	congenital	catheterization	research	collaborative37
Under	review
Impact	of	treatment	strategy	on	outcomes	in	isolated	pulmonary	artery	of	ductal	origin:	a	
multicenter	report	from	the	congenital	catheterization	research	collaborative38
Abstract	Presentation	at	Society	for	
Cardiovascular	Angiography	and	
Interventions	2018
Comparison	of	ductal	arteriosus	stent	and	Blalock‐Taussig	shunt	as	palliation	for	neonates	with	sole	
source	ductal‐dependent	pulmonary	blood	flow:	results	from	the	congenital	catheterization	
research	collaborative39
Abstract	Presentation	at	American	Heart	
Association	2018
Differences	in	somatic	growth	and	mode	of	feeding	by	palliation	strategy	for	infants	with	
ductal‐dependent	pulmonary	blood	flow:	results	from	the	congenital	catheterization	research	
collaborative18
Abstract	Presentation	at	American	Heart	
Association	2018
Comparison	of	outcomes	at	time	of	superior	cavopulmonary	connection	between	single	ventricle	
patients	with	ductal‐dependent	pulmonary	blood	flow	initially	palliated	with	either	Blalock‐Taussig	
shunt	or	ductus	arteriosus	stent:	results	from	the	Congenital	Catheterization	Research	
Collaborative19
Abstract	Presentation	at	American	Heart	
Association	2018
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Whenever	 possible,	 data	 extraction	 for	 specific	 studies	 will	
be	 enhanced	 by	 utilizing	 site‐specific	 data	 warehouses—eg,	
Lumedx	 (Cardiovascular	 Data	 Intelligence,	 Oakland,	 California)	 or	
CardioAccess	 (CardioAccess	 Inc,	 Fort	 Lauderdale,	 Florida)—which	
offer	the	benefit	of	prior	review	and	confirmation	of	all	datapoints	
by	 each	 site's	 internal	 bioinformatics	 team.	 Use	 of	 institutional	
data	 warehouses	 is	 achieved	 using	 common	 diagnostic	 or	 proce-
dural	codes	derived	from	either	the	 Improving	Pediatric	and	Adult	
Congenital	Treatment	(IMPACT)	registry	or	the	Society	of	Thoracic	
Surgeons	 (STS)	 Congenital	 database.26,29	 Use	 of	 these	 common	
codes	across	the	registries	(and	therefore	across	CCRC	centers,	all	
of	 which	 participate	 in	 these	 registries)	 ensures	 standardization,	
appropriate	 patient	 inclusion,	 and	 common	 procedure	 definitions.	
The	CCRC	has	also	 linked	patient	 identifiers	at	 the	center‐level	 to	
Pediatric	Health	Information	System	(PHIS)	data	to	perform	health	
care	cost	comparison	analysis.	These	finance	data	are	then	deidenti-
fied	and	reviewed	and	analyzed	in	a	blinded	manner.
6  | CCRC FUTURE DIREC TIONS
To	 date,	 the	 CCRC	 has	 undertaken	 strictly	 retrospective,	 compre-
hensive	outcomes	 studies	 (Table	2).	Our	current	 study	will	 compare	
midterm	and	late	outcomes	in	symptomatic	(cyanotic)	neonates	with	
tetralogy	of	Fallot	(TOF),	based	upon	initial	treatment	strategy.	The	2	
main	cohorts	will	be	 those	undergoing	primary	neonatal	TOF	 repair	
and	 those	 neonates	 undergoing	 palliation	 (including	 BT	 shunt,	 PDA	
stent,	right	ventricular	outflow	tract	stent,	and	balloon	pulmonary	val-
vuloplasty)	with	subsequent	complete	TOF	repair.	We	anticipate	that	
after	the	creation	of	this	large	multicenter	database,	multiple	derivative	
studies	will	be	undertaken	to	answer	more	focused	clinical	questions.
We	also	aim	to	undertake	prospective,	observational	studies	in-
volving	populations	with	CHD—including	cohorts	previously	studied	
in	a	retrospective	manner.	Future	potential	studies	include	the	eval-
uation	 of	 neurodevelopmental	 outcomes	 following	 catheter‐based	
palliation	 for	 infants	with	 CHD,	 comparative	 studies	 based	 on	 in-
tention‐to‐treat	 analysis	 (which	 is	 unachievable	 in	 a	 retrospective	
study),	 and	observational	 cohort	 studies	of	high‐risk	CHD	 lesions.	
For	these	prospective	studies,	we	anticipate	considerably	increased	
work	burden	at	each	site,	which	will	require	additional	coordinator	
support	to	facilitate	sustained	success.	In	an	effort	to	mitigate	this	
added	effort,	we	plan	to	develop	center‐level	data	linkages	to	exist-
ing	registries,	including	PC4,	PAC3,	STS,	and	IMPACT,	to	reduce	the	
work	burden	of	chart	abstraction.
Lastly,	we	recognize	the	increasing	role—and	at	times	overlap—of	
discipline‐specific	large	multicenter	collaboratives	within	the	field	of	
pediatric	and	adult	congenital	cardiology.	In	order	to	offer	value	not	
just	to	investigator	members,	but	to	the	hospitals	and	academic	insti-
tutions	which	financially	sustain	these	organizations,	many	of	these	
collaboratives	 operate	 within	 the	 sphere	 of	 quality	 improvement	
work.	Quality	improvement	initiatives	further	institutional	missions,	
and	therefore	registry‐based	multicenter	efforts	are	perceived	as	di-
rectly	applicable	in	this	light.	With	the	development	of	prospective	
research	projects,	as	detailed	above,	we	intend	for	the	CCRC	to	offer	
similar	 value,	 with	 access	 to	 continuous	 feedback	 on	 patient	 out-
comes	as	well	as	highly	technical	procedural	details,	in	part	to	facil-
itate	the	introduction	of	novel	treatment	strategies.	Lesion‐specific	
registry	development	may	also	be	a	 focus	of	 future	CCRC	work	to	
facilitate	discrete	quality	 improvement	 efforts	 related	 to	 interven-
tional	 procedures	 and	 their	 outcomes.	We	 also	 plan	 to	 study	 pa-
tient‐reported	outcomes	 in	 future	studies,	 taking	advantage	of	 the	
existing	and	ensuing	 identified	populations.	We	anticipate	that	 the	
CCRC	will	continue	to	evolve,	from	a	retrospective‐based	research	
collaborative	into	a	multicenter	prospective	research	group	focusing	
on	 improving	 outcomes,	 establishing	 procedural	 benchmarks,	 and	
performing	comparative	research.	We	believe	that	hypothesis‐driven	
research	 is	a	critical	 tool	 for	quality	 improvement,	and	data‐driven	
clinical	decision	making	leads	to	optimized	care	of	patients	with	CHD.
7  | CONCLUSION
The	CCRC	is	a	multicenter	research	collaborative	which	aims	to	im-
prove	the	health	and	well‐being	of	patients	with	CHD.	Our	approach	
of	utilizing	highly	granular	clinical	data	allows	us	to	evaluate	patient‐
specific	and	procedural	factors	and	their	effect	on	outcomes	follow-
ing	interventions.	Our	goal	 is	to	provide	scientific	data	to	optimize	
clinical	decision	making,	particularly	where	controversy	or	disagree-
ment	exists.	We	believe	that	the	CCRC,	through	partnerships	with	
existing	cardiac	registries	and	with	our	institutional	colleagues,	will	
help	 improve	 our	 understanding	 of	 the	 outcomes	 following	 CHD	
interventions.
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